PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17495969-3	2007	Here, we investigated the potential synergy of bortezomib and ATO on Bcr-Abl(+) leukemic K562 cells.	Arsenic Trioxide	62-65	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	69-76	
17495969-4	2007	The results showed that cotreatment of bortezomib at 32 nM, a half concentration for growth arrest, and ATO at 1 microM, a dose with no significant cytotoxic effect, synergistically induced apoptosis in the cell line, followed by enhanced mitochondrial dysfunction, release of cytochrome c and apoptosis-inducing factor, caspase-3 cleavage and degradation of poly-adenosine diphosphate-ribose polymerase together with the decreased Bcr-Abl protein.	Arsenic Trioxide	104-107	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	432-439